Subscribe to Biotech Blueprint at biotechblueprint.com In today's episode:How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
--------
51:45
--------
51:45
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77
Subscribe to Biotech Blueprint for free at biotechblueprint.com.Pfizer’s courtroom gamble to block Novo Nordisk’s $10B Metsera takeover failed, and Novo immediately fired back with an even higher bid, leaving Pfizer two days to respond before the Nov. 13 vote. Meanwhile, Trump struck landmark pricing deals with Novo and Lilly to bring GLP-1 drugs like Ozempic and Mounjaro to Medicare at $245 a month. Moderna tightened its belt and beat expectations with $1 B in revenue, J&J scored an FDA win for Caplyta in depression, and Viking’s next-gen GLP-1 showed it can actually reverse metabolic syndrome.
--------
6:58
--------
6:58
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com.
Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.
For more content, please subscribe to biotechblueprint.substack.com.